20 (AIDX) Receivables (2024 - 2026)

20 (AIDX) reported Receivables of $201481.0 for Q1 2026, up 0.76% quarter-over-quarter from $199954.0 in Q4 2025.

20 (AIDX) Receivables (2024 - 2026) Analysis & Trends

20 has reported Receivables for 3 years, with the latest figure at $201481.0 in Q1 2026.

For the quarter ending Q1 2026, Receivables changed N/A year-over-year to $201481.0; the trailing twelve-month figure through Mar 2026 stood at $201481.0 (changed N/A YoY), and the FY2025 full-year result was $199954.0, up 47.82% from the prior year.
Receivables for Q1 2026 stood at $201481.0, up from $199954.0 in the prior quarter.
The five-year high for Receivables was $201481.0 in Q1 2026, with the low at $135272.0 in Q4 2024.
Historically, Receivables has averaged $178902.3 across 3 years, with a median of $199954.0 in 2025.
The largest YoY upside for Receivables was 47.82% in 2025 against a maximum downside of 47.82% in 2025.
20's Receivables stood at $135272.0 in 2024, then surged by 47.82% to $199954.0 in 2025, then gained by 0.76% to $201481.0 in 2026.
The last three Receivables figures came in at $201481.0 (Q1 2026), $199954.0 (Q4 2025), and $135272.0 (Q4 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Abbott Laboratories	154.42 Bn	147.76 Bn	6.27 Bn	8.21 Bn
2	Stryker	118.12 Bn	115.25 Bn	3.81 Bn	3.57 Bn
3	Medtronic	101.72 Bn	93.55 Bn	5.76 Bn	6.36 Bn
4	Boston Scientific	67.19 Bn	65.98 Bn	3.61 Bn	3.15 Bn
5	Edwards Lifesciences	50.69 Bn	47.02 Bn	1.29 Bn	973.00 Mn
6	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	3.82 Bn
7	Dexcom	28.09 Bn	26.97 Bn	750.30 Mn	1.11 Bn
8	GE HealthCare Technologies	28.08 Bn	26.02 Bn	1.98 Bn	4.50 Bn
9	Steris	19.80 Bn	19.37 Bn	697.10 Mn	1.09 Bn
10	20	-	-	62,884.00	201,481.00

Download Data